Allergan Aesthetics to Present New Data at 2024 American Society for Dermatologic Surgery (ASDS) to Showcase Depth Across Facial Aesthetics and Insight into Patient Perception

News provided by

Oct 16, 2024, 08:00 ET

A total of 12 abstracts, including four Best of Cosmetic Abstracts, demonstrate Allergan Aesthetics' commitment to patient outcomes and detailed insights and understanding of key concerns across differentiated patient segments
Insightful panel discussion with Dr. Kavita Mariwalla, ASDS President Elect (2026) and double board-certified dermatologist, on impact of social media on patient experience and expectations when considering aesthetic treatment

IRVINE, Calif., Oct. 16, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), will present data highlighting efficacy, safety and patient-reported outcomes across its facial injectable portfolio during the 2024 American Society of Dermatologic Surgery (ASDS) Annual Meeting, October 17-20, 2024 in Orlando, Florida. Presentations and a panel discussion demonstrate Allergan Aesthetics' commitment to understanding patient sentiment and developing differentiated treatments to address key aesthetic concerns.

"Allergan Aesthetics has one of the most robust portfolios for aesthetics innovation and continues to lead the industry in innovation. Conducting research that helps ensure safe and optimal outcomes for our differentiated treatments is critical to the future of the aesthetics industry," said, Sara Sangha, Head of U.S. Aesthetics Medical Affairs at Allergan Aesthetics. "As the global aesthetic brand that medical providers and patients know and trust, our commitment to serving and growing the industry with new products, indications and appeal to diverse and new patients is advanced by the research and data presented at ASDS."

Notable presentations, including the below selected as "Best of" Cosmetic, highlight efficacy and safety data of facial injectables, including:

Safety and patient-reported outcomes from a Phase 3 open-label extension study of onabotulinumtoxinA (BOTOX® Cosmetic) for the treatment of platysma bands.
Patient satisfaction after receiving JUVEDERM VOLUMA XC for injection in the temple region to improve moderate to severe temple hollowing in adults over the age of 21.

Additional presentations, including one selected as "Best of" Cosmetic, showcase in-depth detail from a 4,000-subject study across ethnic, racial and gender groups and highlighting key aesthetic concerns by patient segments. The findings from this study, the largest in the U.S., suggest that interest in professionally administered aesthetic treatments for face and body vary among demographic groups and differ from what current aesthetic paradigms suggest.

Data from the following self-identified patient demographics was included:

Females
- Black
- Hispanic/Latina
- White
- Asian
Males

Allergan Aesthetics is also hosting a thought-provoking conversation around social integrity in the aesthetics industry as featured in 'Moving the Needle on Ethics'—the industry-first global collation of thought-leadership essays from Allergan Aesthetics. The panel will spark an open dialogue focusing on the trends in social media usage to promote aesthetics products and procedures and the importance of ethical practices to industry integrity.

The conversation will be led by author, Dr. Mariwalla, and feature expert voices including Dr. Evan Rieder, double-board-certified dermatologist and psychiatrist, Dr. DiAnne Davis, board-certified dermatologist and Dr. Fatima Fahs, board-certified dermatologist and social media expert as moderator.

This panel will take place on Thursday, October 17^th at 12 noon ET in the Special Events Room.

Allergan Aesthetics abstracts at ASDS 2024 are outlined below. The 2024 ASDS video posters can be viewed in "Video Oral Abstract" kiosk areas in the Exhibit Hall.

"Best of Cosmetic" Live Presentation Saturday October 19, 2024 at 8:30-9:30 AM Gatlin Ballroom A3/A4
Abstract Title	Physician Name/Primary Author
Hyaluronic Acid Filler VYC-20L for Correction of Temple Hollowing Yields High Satisfaction, Improvement in Facial and Temple Appearance, and Sustained Effect Across Age, Gender, and Skin Phototypes	José R Montes, MD
Patient-Reported Outcomes Across Repeat Treatments for Moderate to Severe Platysma Prominence with OnabotulinumtoxinA in a Long-term, Phase 3, Open-label Extension Study	Shannon Humphrey, MD, FRCPC, FAAD
Repeat Treatments of Moderate to Severe Platysma Prominence With OnabotulinumtoxinA Has a Favorable Safety Profile in a Long-term, Phase 3, Open-label Extension Study	Terrence Keaney, MD, FAAD
Interest in professionally administered aesthetic treatments for face and body: Results from Black female-identifying respondents of a large survey of aesthetically inclined adults in the US	Michelle Henry, MD

Maximum Difference VIDEO Poster Abstract Presentation Can be viewed in "Video Oral Abstract" kiosk areas in the Exhibit Hall
Abstract Title	Physican Name/Primary Author
Interest in professionally administered aesthetic treatments for face and body: Results from Hispanic/Latina female- identifying respondents of a large survey of aesthetically inclined adults in the US	Vivian Bucay, MD, FAADboard-certified dermatologist
Interest in professionally administered aesthetic treatments for face and body: Results from White female-identifying respondents to a large survey of aesthetically inclined adults in the US	Deirdre Hooper, MD
Interest in professionally administered aesthetic treatments for face and body: Results from Asian female-identifying respondents of a large survey of aesthetically inclined adults in the US	Annie Chiu, MD, FAAD
Interest in professionally administered aesthetic treatments for face and body: Results from male and female respondents of a large survey of aesthetically inclined adults in the US	Terrence Keaney, MD, FAAD

Facial – VIDEO Poster Abstract Presentation Can be viewed in "Video Oral Abstract" kiosk areas in the Exhibit Hall
Abstract Titles	Physican Name/Primary Author
Infraorbital and Periorbital Rejuvenation With Sequential Use of Hyaluronic Acid-Fillers and OnabotulinumtoxinA	Samira Baharlou, MD
Patient-Reported Outcomes After Infraorbital and Periorbital Rejuvenation Using Sequential Hyaluronic Acid- Fillers and OnabotulinumtoxinA Treatments	Gregory Goodman, MD
OnabotulinumtoxinA for the Treatment of Platysma Prominence: Patient-Reported Outcomes From Two Phase 3 Multicenter, Randomized, Double-Blind, Placebo- Controlled Studies	Joely Kaufman, MD
Treating Platysma Prominence with OnabotulinumtoxinA: Safety and Efficacy Results from a Phase 3 Multicenter, Randomized, Double-blind, Placebo-Controlled Study	Sabrina Fabi, MD

About Allergan Aesthetics

At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

SOURCE AbbVie